3-nitropropionic acid has been researched along with Parkinson Disease, Secondary in 7 studies
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE
3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We developed a primate model of striatonigral degeneration (SND), the neuropathology underlying levodopa-unresponsive parkinsonism associated with multiple systemic atrophy (MSA-P), by sequential systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3NP) in a Macaca fascicularis monkey." | 1.31 | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. ( Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK, 2000) |
| "Cotreatment with riluzole (4 mg/kg i." | 1.30 | Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. ( Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tantucci, M | 1 |
| Mariucci, G | 1 |
| Taha, E | 1 |
| Spaccatini, C | 1 |
| Tozzi, A | 1 |
| Luchetti, E | 1 |
| Calabresi, P | 1 |
| Ambrosini, MV | 1 |
| Imamura, K | 1 |
| Takeshima, T | 1 |
| Kashiwaya, Y | 1 |
| Nakaso, K | 1 |
| Nakashima, K | 1 |
| Ayala, A | 1 |
| Venero, JL | 1 |
| Cano, J | 1 |
| Machado, A | 1 |
| Palfi, S | 2 |
| Riche, D | 1 |
| Brouillet, E | 1 |
| Guyot, MC | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Peschanski, M | 1 |
| Stutzmann, JM | 1 |
| Hantraye, P | 1 |
| Klivenyi, P | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Beal, MF | 1 |
| Leventhal, L | 1 |
| Goetz, CG | 1 |
| Hantraye, T | 1 |
| Roitberg, BZ | 1 |
| Sramek, J | 1 |
| Emborg, M | 1 |
| Kordower, JH | 1 |
| Ghorayeb, I | 1 |
| Fernagut, PO | 1 |
| Aubert, I | 1 |
| Bezard, E | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Tison, F | 1 |
1 review available for 3-nitropropionic acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Mitochondrial toxins and neurodegenerative diseases.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Mitochondria; MPTP Poisoning; Neurodege | 2007 |
6 other studies available for 3-nitropropionic acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment.
Topics: Animals; Corpus Striatum; Electron Transport Complex I; Electron Transport Complex II; Heat-Shock Re | 2009 |
D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease.
Topics: 3-Hydroxybutyric Acid; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Dopamine; Fluorescent | 2006 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; | 1997 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys.
Topics: Animals; Basal Ganglia; Brain Mapping; Cebus; Chorea; Dystonia; Mitochondria; Neurotoxins; Nitro Com | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |